Panacea Venture Reduces Stake in Atara Biotherapeutics with $489K Share Sale
ATRA is trading near its 52-week low of $4.252 (7.7% above the low) on elevated volume (4.0× avg).
Summary
Panacea Venture, a 10% owner, sold 80,554 shares of Atara Biotherapeutics common stock for approximately $489,000, reducing its overall beneficial ownership to 19.99%.
Key Events · Ownership and Investor Activity · ATRA
-
Significant Share Sale
Panacea Venture Healthcare Fund II, L.P. sold 80,554 shares of common stock on January 12, 2026, at a weighted average price of $6.0707 per share, totaling approximately $489,000.
-
Warrant Exercise
Panacea Opportunity Fund I, L.P. exercised warrants to purchase 48,736 shares of common stock on November 28, 2025.
-
Current Beneficial Ownership
Following these transactions, Panacea Innovation Limited and its affiliated funds beneficially own an aggregate of 1,632,345 shares, representing 19.99% of the outstanding common stock.
Analysis · ATRA · Life Sciences
Panacea Venture, a significant institutional investor, reported a sale of shares in Atara Biotherapeutics. This transaction represents a notable reduction in its holdings, potentially signaling a shift in investment strategy or a move to rebalance its portfolio. For a company of Atara Biotherapeutics' market capitalization, a sale of this magnitude by a large investor is an important event for the market to consider.
At the time of this filing, ATRA was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.2M. The 52-week trading range was $4.25 to $19.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.